Research programme: sialylated immunoglobulins - Momenta Pharmaceuticals

Drug Profile

Research programme: sialylated immunoglobulins - Momenta Pharmaceuticals

Alternative Names: hsIVIg; Hyper-sialylated IVIg; M 254; sFc; Sialylation research program - Momenta; sIVIG; Tetra-Fc-sialylated immunoglobulins - Momenta Pharmaceuticals

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Virdante Pharmaceuticals
  • Developer Momenta Pharmaceuticals
  • Class Immunoglobulins; Recombinant proteins
  • Mechanism of Action C-type lectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 02 May 2017 Momenta Pharmaceuticals plans a clinical trial for M 254 in 2018
  • 19 Dec 2016 Sialylated immunoglobulins of Momenta Pharmaceuticals are available for licensing as of 19 Dec 2016. www.momentapharma.com
  • 08 Jul 2015 Early research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top